MX2022008746A - Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos. - Google Patents

Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos.

Info

Publication number
MX2022008746A
MX2022008746A MX2022008746A MX2022008746A MX2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A MX 2022008746 A MX2022008746 A MX 2022008746A
Authority
MX
Mexico
Prior art keywords
methods
same
treating diseases
peptide compounds
disclosed
Prior art date
Application number
MX2022008746A
Other languages
English (en)
Spanish (es)
Inventor
Eran Ovadia
Avi Ben-Shimon
Ilana Cohen
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of MX2022008746A publication Critical patent/MX2022008746A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
MX2022008746A 2020-01-15 2021-01-14 Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos. MX2022008746A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL272074A IL272074B2 (en) 2020-01-15 2020-01-15 Peptide compounds and methods of treating diseases using same
PCT/IL2021/050044 WO2021144798A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same

Publications (1)

Publication Number Publication Date
MX2022008746A true MX2022008746A (es) 2022-10-13

Family

ID=76863930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008746A MX2022008746A (es) 2020-01-15 2021-01-14 Compuestos de peptidos y procedimientos de tratamiento de enfermedades que usan los mismos.

Country Status (12)

Country Link
US (1) US20230049549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4090347A1 (cg-RX-API-DMAC7.html)
JP (1) JP7809060B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220145826A (cg-RX-API-DMAC7.html)
CN (6) CN119708143A (cg-RX-API-DMAC7.html)
AU (1) AU2021207415B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022013978A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167139A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011101A2 (cg-RX-API-DMAC7.html)
IL (1) IL272074B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022008746A (cg-RX-API-DMAC7.html)
WO (1) WO2021144798A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7395517B2 (ja) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
WO2003037172A2 (en) * 2001-11-01 2003-05-08 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
AU2005276117C1 (en) * 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
US8648045B2 (en) * 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
EP2331564A4 (en) * 2008-10-06 2013-02-20 Carolus Therapeutics Inc PROCESS FOR TREATMENT OF IGNITION
US20130096070A1 (en) * 2009-04-07 2013-04-18 University Of Kansas Peptide targeting of inner ear cells
EP3263127B1 (en) * 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
CA3172682A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
JP7395517B2 (ja) * 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途

Also Published As

Publication number Publication date
BR112022013978A2 (pt) 2022-10-11
IL272074B2 (en) 2024-12-01
CO2022011101A2 (es) 2022-11-08
CN119708143A (zh) 2025-03-28
IL272074B1 (en) 2024-08-01
CN119708142A (zh) 2025-03-28
IL272074A (en) 2021-07-29
CN119708141A (zh) 2025-03-28
CN115942948B (zh) 2025-01-14
CN115942948A (zh) 2023-04-07
EP4090347A1 (en) 2022-11-23
JP2023510019A (ja) 2023-03-10
US20230049549A1 (en) 2023-02-16
CN119708144A (zh) 2025-03-28
AU2021207415A1 (en) 2022-09-08
KR20220145826A (ko) 2022-10-31
AU2021207415B2 (en) 2026-08-13
WO2021144798A1 (en) 2021-07-22
JP7809060B2 (ja) 2026-01-30
CN119708140A (zh) 2025-03-28
CA3167139A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
CL2018003322A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128)
CO2021016768A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CL2021000387A1 (es) Compuestos de anillo fusionado
CL2024003895A1 (es) Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso.
CO2022000260A2 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
MX2021008191A (es) Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
AR069409A1 (es) Variantes de peptidos natriureticos de tipo c
PE20260442A1 (es) Composiciones y metodos para tratar la enfermedad celiaca
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
CL2025002554A1 (es) Compuestos tricíclicos inhibidores de parp1 y uso para tratar cáncer.
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
CO2026005573A2 (es) Compuestos heterobifuncionales y métodos de tratamiento de enfermedades
ECSP21002804A (es) Apirasas solubilizadas, métodos y usos
EP4069715A4 (en) PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION
CO2019003865A2 (es) Proteína terapéutica
CO2022011101A2 (es) Compuestos de péptidos y procedimientos de tratamiento de enfermedades que usan los mismos
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina